Sep 29, 2021

In recognition of this last day of September and the close of Blood Cancer Awareness Month, FORUS Therapeutics Inc. is pleased to announce that Health Canada has accepted for review the New Drug Submission (NDS) for once-weekly XPOVIO® (selinexor) in combination with bortezomib and low-dose dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
This is a remarkable moment in the history of FORUS and a major milestone in our efforts to bring an important new treatment option to people living with multiple myeloma. We remain committed to the broader multiple myeloma community and look forward to bringing this therapy to patients as soon as possible.


Font Resize